Novo, Lilly Weight-Loss Drugs May Help Alzheimer’s Patients—and Stock Prices
1. Novo Nordisk's stock down over 60% since mid-2024, valuation concerns persist. 2. Positive trial results for Alzheimer’s could substantially impact stock prices. 3. Eli Lilly could see a 10% boost from Novo’s successful trials. 4. Current Alzheimer's medication options have significant side effects. 5. FDA review of Novo’s Wegovy oral pill could enhance market presence.